Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe haemophilia A (FVIII level less than or equal to 1%)~* Treatment history of more than 150 exposure days with recombinant or plasma-derived FVIII replacement products~* HIV or HCV negative, or if positive the patient is on a stable antiviral regimen at the time of the enrolment in the trial~Exclusion Criteria:~* Presence of any bleeding disorder in addition to haemophilia A~* Inhibitor titre greater than or equal to 0.6 Bethesda Units (BU) at screening and past history of inhibitor~* Abnormal renal function tests~* Known hypersensitivity to Advate®

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Advate®/turoctocog alfa (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).